Biospecimen (Visscher)

乳腺孢子生物标本和病理中心负责为乳腺孢子生物标本库添加和处理新的生物标本，并使这些标本可用于孢子的四个主要项目，并很可能用于发展研究和职业发展计划。生物标本也将提供给从事乳腺癌转化研究的其他内部和外部研究人员。乳房孢子行动委员会将审议有关生物标本的请求，重点是科学价值和标本及其分析所需相关数据的可得性。来自生物统计学和患者登记核心的输入包括在组织请求的评估中。生物标本中心的病理小组将在乳腺病理数据库中为选定的患者群体提供冷冻和福尔马林固定石蜡包埋组织的详细注释，以支持SPORE项目和乳腺生物标本库提供组织的其他项目。核心病理小组也将解释免疫组化染色。生物标本和病理学核心将与梅奥诊所癌症中心生物标本接入和处理共享资源协调，处理血液样本以提供基因组DNA和血清等分，并与组织和细胞分子分析共享资源合作，提供组织学和其他组织基础服务，包括石蜡和冷冻切片、免疫组织化学、组织微阵列构建和数字成像。与现有的基础设施（如这些共享资源）紧密合作，可以最大限度地减少服务冗余，并利用现有的经验和最先进的设备。生物标本和病理学中心将开发新的免疫染色方法，以及构建细胞系组织微阵列，以筛选和测试用于福尔马林固定、石蜡包埋组织的免疫染色抗体。

The Biospecimen and Pathology Core ofthe Breast SPORE is responsible for accessioning and processing new biospecimens for the Breast SPORE Biospecimen Repository and to make those specimens available for use in the four SPORE main projects and very likely for the Developmental Research and Career Development Programs. Biospecimens will also be made available to other intra- and extra-mural investigators engaged in breast cancer translational research. Requests for biospecimens will be taken under consideration by the Breast SPORE Operations Committee, with a heavy emphasis on scientific merit and on availability of specimens and their associated data needed for analysis. Input from the Biostatistics and Patient Registry Core is included in the evaluation of requests for tissues. The Pathology Team of the Biospecimen Core will provide detailed annotations in the Breast Pathology Database for frozen and formalin-fixed paraffin-embedded tissues from selected cohorts of patients to support SPORE projects and additional projects for which the Breast Biospecimen Repository has provided tissues. The Core pathology team will also interpret IHC staining. The Biospecimen and Pathology Core will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing Shared Resource to process blood samples to provide genomic DNA and serum aliquots, and with the Tissue and Cell Molecular Analysis Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state ofthe art equipment. New immunostaining assays will be developed by the Biospecimen and Pathology Core, as well as construction of cell line tissue microarrays to screen and test antibodies for immunostaining formalin-fixed, paraffin-embedded tissues.